Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 2, 2026 14 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Even If Insured, People with Advanced Cancer Often Face Financial Problems January 26, 2022 Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 Classmates Surprise Badly Bullied Teen After Weeks Of Planning: ‘You Deserve... March 29, 2019 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 Load more HOT NEWS For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... French Senate Committee Backs ESMO Call to Revise EU Regulation to... EMA Recommends Extension of Indications for Olaparib
